MapLight Therapeutics (MPLT) Cash from Financing Activities (2024 - 2025)

MapLight Therapeutics (MPLT) reported Cash from Financing Activities of $272.0 million for Q4 2025, up 5439200.0% on a YoY basis from N/an in Q4 2024, and up 5439200.0% sequentially from $5000.0 in Q4 2024.

MapLight Therapeutics (MPLT) Cash from Financing Activities (2024 - 2025) Analysis & Trends

MapLight Therapeutics (MPLT) has 2 years of Cash from Financing Activities data on file, last reported at $272.0 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - 30.14 Mn
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 68.63 Mn
4 NuCana 279.75 Bn 279.75 Bn - 9,311.16
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn -538.80 Mn
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -802.20 Mn
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn -
9 Revolution Medicines 37.78 Bn 37.78 Bn - 238.74 Mn
10 MapLight Therapeutics 305.82 Mn 305.82 Mn - 271.97 Mn

Historic Data

Download Data
DateValue
Dec 31, 2025 271.97 Mn
Dec 31, 2025 271.97 Mn
Dec 31, 2024 5,000.00
Dec 31, 2024 5,000.00